8-K: Phathom Pharmaceuticals Reports Strong First Full Year of VOQUEZNA Launch with $55.3 Million in Net Revenue

Phathom Pharmaceuticals announces its fourth quarter and full year 2024 financial results, highlighting $55.3 million in net revenue for VOQUEZNA's first full year and a Phase 2 EoE trial nearing initiation.

Summary

• Phathom Pharmaceuticals reported its fourth quarter and full year 2024 financial results on March 6, 2025.
• VOQUEZNA generated $55.3 million in net revenues for the full year 2024, with $29.7 million in Q4, representing an 81% increase from Q3.
• Over 300,000 prescriptions for VOQUEZNA products have been filled since launch, a 110% increase since the last earnings report.
• The company plans to initiate a Phase 2 trial for VOQUEZNA in eosinophilic esophagitis (EoE) with first patient enrollment expected in Q2 2025.
• Net loss for the full year 2024 was $334.3 million, compared to $201.6 million for the full year ended 2023.
• As of December 31, 2024, cash and cash equivalents were $297.3 million.
• The company believes its current resources will be sufficient to fund operations and achieve cash flow positivity.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company shows strong revenue growth for VOQUEZNA and is expanding its clinical programs. However, the increasing net losses and SG&A expenses are concerning, tempering the overall positive outlook.

Positives

• VOQUEZNA achieved significant commercial progress in 2024, establishing itself as a treatment for GERD sufferers.
• The breadth and depth of VOQUEZNA's prescriber base is continuing to expand.
• VOQUEZNA has strong commercial coverage, with over 120 million covered lives having access to the tablets.
• The company launched its first broadcast ad and full-scale direct-to-consumer (DTC) campaign, 'VOQUEZNA Can Kick Some Acid', to drive awareness.
• Phathom is advancing alternative formulation work, including the development of an orally disintegrating tablet (ODT), which, if successful, could offer extended intellectual property (IP) protection and the potential to broaden use across diverse patient populations with further studies, including pediatric and EoE patients.
• The company believes its current resources will be sufficient to fund operations and achieve cash flow positivity.

Negatives

• The net loss for the year ended 2024 was $334.3 million, significantly higher than the $201.6 million loss in 2023.
• SG&A expenses for the full year 2024 were $290.7 million, an increase of $172.8 million compared to 2023.

Risks

• The company's ability to successfully commercialize VOQUEZNA depends on coverage and reimbursement levels from governmental authorities and health insurers, as well as market acceptance by healthcare providers.
• The company may use its capital resources sooner than expected, or its operating plan may overestimate its expected product revenues, which could require it to reduce expenses or raise additional capital sooner than expected.
• Unexpected adverse side effects or inadequate efficacy of vonoprazan may limit its development, regulatory approval, and/or commercialization.
• The FDA may reject Phathom's request to correct the Orange Book listings identifying the expiration date for the NCE exclusivity period on the VOQUEZNA tablets Orange Book listings.
• Phathom may face competition earlier than expected if it loses or fails to obtain any of its patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets.

Future Outlook

The company believes its current cash resources, operating plan, estimated product revenues, and potential funds available under its existing term loan will be sufficient to fund operations and enable Phathom to achieve cash flow positivity.

Management Comments

• VOQUEZNA's first full year on the market has been exceptional, with impressive commercial execution, increasing brand recognition, and growing demand, said Terrie Curran, President and CEO of Phathom.
• With total filled prescriptions rising and positive brand experiences reinforcing VOQUEZNA's differentiated value, we believe we are on the path to blockbuster success and remain confident that the strong foundation we have built will propel sustained growth.

Industry Context

Phathom is operating in the competitive gastrointestinal disease market, focusing on GERD and H. pylori treatments. The launch of VOQUEZNA represents a novel approach with its potassium-competitive acid blocker (PCAB) mechanism, differentiating it from traditional proton pump inhibitors (PPIs). The company's focus on direct-to-consumer advertising and expanding its prescriber base reflects common strategies in the pharmaceutical industry to drive market adoption.

Comparison to Industry Standards

• VOQUEZNA's $55.3 million in first-year revenue is a solid start, but it's important to compare it to other recently launched GI drugs.
• For example, Takeda's Gattex, a treatment for short bowel syndrome, achieved approximately $127 million in its first full year after launch.
• However, VOQUEZNA targets a much larger market (GERD) than Gattex, so the potential for growth is significant.
• The 80% commercial coverage is competitive with other branded GI drugs, but maintaining and expanding this coverage will be crucial.
• Key competitors in the GERD space include established PPIs like omeprazole (Prilosec) and esomeprazole (Nexium), as well as newer entrants like Dexilant (dexlansoprazole).
• VOQUEZNA's PCAB mechanism offers a potential advantage over PPIs in terms of faster and more consistent acid suppression.

Stakeholder Impact

• Shareholders: The financial results and business updates provide insights into the company's performance and future prospects, potentially influencing investment decisions.
• Employees: The company's growth and expansion plans may create new opportunities for employees.
• Customers (Patients): The development and commercialization of VOQUEZNA offer a new treatment option for GERD and H. pylori infection.
• Healthcare Providers: The increasing prescriber base indicates growing acceptance and utilization of VOQUEZNA among healthcare professionals.
• Suppliers: The company's manufacturing and supply chain partners benefit from the increased demand for VOQUEZNA.
• Creditors: The company's financial stability and cash runway are important factors for creditors.

Next Steps

• Initiate Phase 2 study evaluating VOQUEZNA as a potential treatment for eosinophilic esophagitis (EoE) in adults and adolescents, with first subject enrollment planned for Q2 2025.
• Continue to analyze real-world data from the launch of VOQUEZNA for Non-Erosive GERD to inform the potential timing and value of advancing a dedicated Phase 3 program to evaluate As Needed (On-Demand) dosing of VOQUEZNA for active heartburn episodes.
• Await FDA response to the Citizen Petition (CP) requesting the correction of the Orange Book listings for VOQUEZNA 10 mg and 20 mg tablets.
• Launch a new DTC campaign by the end of March 2025, aimed at further increasing brand awareness and consumer demand for VOQUEZNA.

Key Dates